Nuvectis Pharma (NVCT) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $18.60, -1.74% vs the prior close of $18.93.
- Volume 158.42K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NVCT dips 1.7% to $18.60. Closed at $18.60, -1.74% vs the prior close of $18.93. Day range $17.81–$18.89, opened at $18.89.
NVCT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NVCT dips 1.7% to $18.60
- Closed at $18.60, -1.74% vs the prior close of $18.93. Day range $17.81–$18.89, opened at $18.89.
- Volume was 158.42K shares, 0.8x its 50-day average of 197.67K.
- Price is -13.9% vs its 50-day average ($21.61) and +32.3% vs its 200-day average ($14.06).
- 52-week range $5.55–$29.27; today's close sits at 55% of that range, 36.5% below the 52-week high.
Oct 15, 2026 — NVCT jumps 5.2% to $18.93
- Closed at $18.93, +5.17% vs the prior close of $18.00. Day range $18.30–$19.59, opened at $18.30.
- Volume was 156.90K shares, 0.8x its 50-day average of 198.93K.
- Price is -12.4% vs its 50-day average ($21.62) and +35.1% vs its 200-day average ($14.01).
- 52-week range $5.55–$29.27; today's close sits at 56% of that range, 35.3% below the 52-week high.
Oct 14, 2026 — NVCT dips 0.8% to $18.00, a 3-month low, 3 down days in a row
- Closed at $18.00, -0.83% vs the prior close of $18.15. Day range $17.68–$18.72, opened at $18.27.
- Volume was 184.20K shares, 0.9x its 50-day average of 207.09K.
- Price is -16.8% vs its 50-day average ($21.62) and +29.0% vs its 200-day average ($13.95).
- 52-week range $5.55–$29.27; today's close sits at 52% of that range, 38.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — NVCT slides 7.8% to $18.15, a 1-month low
- Closed at $18.15, -7.82% vs the prior close of $19.69. Day range $18.01–$19.88, opened at $19.59.
- Volume was 215.80K shares, 1.0x its 50-day average of 206.87K.
- Price is -16.2% vs its 50-day average ($21.66) and +30.6% vs its 200-day average ($13.90).
- 52-week range $5.55–$29.27; today's close sits at 53% of that range, 38.0% below the 52-week high.
Oct 12, 2026 — NVCT slides 6.8% to $19.69, a 1-month low
- Closed at $19.69, -6.77% vs the prior close of $21.12. Day range $19.55–$21.19, opened at $21.12.
- Volume was 145.80K shares, 0.7x its 50-day average of 207.13K.
- Price is -9.4% vs its 50-day average ($21.73) and +42.2% vs its 200-day average ($13.85).
- 52-week range $5.55–$29.27; today's close sits at 60% of that range, 32.7% below the 52-week high.
Oct 9, 2026 — NVCT jumps 4.9% to $21.12
- Closed at $21.12, +4.92% vs the prior close of $20.13. Day range $19.88–$21.29, opened at $20.11.
- Volume was 153.00K shares, 0.7x its 50-day average of 210.06K.
- Price is -3.0% vs its 50-day average ($21.77) and +53.2% vs its 200-day average ($13.79).
- 52-week range $5.55–$29.27; today's close sits at 66% of that range, 27.9% below the 52-week high.
Oct 8, 2026 — NVCT dips 0.8% to $20.13
- Closed at $20.13, -0.79% vs the prior close of $20.29. Day range $19.60–$20.42, opened at $20.05.
- Volume was 179.40K shares, 0.8x its 50-day average of 212.23K.
- Price is -7.7% vs its 50-day average ($21.80) and +46.7% vs its 200-day average ($13.72).
- 52-week range $5.55–$29.27; today's close sits at 61% of that range, 31.2% below the 52-week high.
Oct 7, 2026 — NVCT rises 1.3% to $20.29
- Closed at $20.29, +1.30% vs the prior close of $20.03. Day range $19.67–$20.72, opened at $19.67.
- Volume was 121.10K shares, 0.6x its 50-day average of 213.71K — lighter than usual.
- Price is -7.0% vs its 50-day average ($21.81) and +48.5% vs its 200-day average ($13.66).
- 52-week range $5.55–$29.27; today's close sits at 62% of that range, 30.7% below the 52-week high.
Oct 6, 2026 — NVCT slides 6.4% to $20.03, a 1-month low
- Closed at $20.03, -6.36% vs the prior close of $21.39. Day range $19.79–$21.54, opened at $21.54.
- Volume was 188.10K shares, 0.9x its 50-day average of 212.88K.
- Price is -8.1% vs its 50-day average ($21.80) and +47.3% vs its 200-day average ($13.60).
- 52-week range $5.55–$29.27; today's close sits at 61% of that range, 31.6% below the 52-week high.
Oct 5, 2026 — NVCT dips 2.4% to $21.39
- Closed at $21.39, -2.42% vs the prior close of $21.92. Day range $20.29–$22.24, opened at $22.00.
- Volume was 194.30K shares, 0.9x its 50-day average of 213.96K.
- Price is -1.9% vs its 50-day average ($21.79) and +58.0% vs its 200-day average ($13.54).
- 52-week range $5.55–$29.27; today's close sits at 67% of that range, 26.9% below the 52-week high.
Oct 2, 2026 — NVCT jumps 5.8% to $21.92
- Closed at $21.92, +5.79% vs the prior close of $20.72. Day range $21.04–$22.00, opened at $21.11.
- Volume was 207.50K shares, 1.0x its 50-day average of 216.32K.
- Price is +0.8% vs its 50-day average ($21.75) and +62.7% vs its 200-day average ($13.47).
- 52-week range $5.55–$29.27; today's close sits at 69% of that range, 25.1% below the 52-week high.
NVCT latest news & SEC filings
Every SEC filing by or about NVCT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 28, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 21, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$7.02M (prior year -$6.33M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.30 (prior year -$0.30) ( vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mosseri Marlio Charles bought 50,000 shares at $18.32 (≈$916.00K) on Jun 30, 2026
- Mosseri Marlio Charles bought 50,000 shares at $18.32 (≈$916.00K) on Jun 30, 2026
- Mosseri Marlio Charles bought 50,000 shares at $18.32 (≈$916.00K) on Jun 30, 2026
- Mosseri Marlio Charles bought 50,000 shares at $18.32 (≈$916.00K) on Jun 30, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bentsur Ron bought 12,500 shares at $20.00 (≈$250.00K) on Jun 30, 2026
- Bentsur Ron bought 12,500 shares at $20.00 (≈$250.00K) on Jun 30, 2026
- Bentsur Ron bought 12,500 shares at $20.00 (≈$250.00K) on Jun 30, 2026
- Bentsur Ron bought 12,500 shares at $20.00 (≈$250.00K) on Jun 30, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Jun 30, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 29, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade NVCT
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 11, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.76% (largest 8.4%). That is a volatile stock.
- Liquidity: about 176.03K shares (≈$3.27M) trade per day on average.
- 52-week position: $18.60 vs a range of $5.55–$29.27 (55% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Ron Bentsur bought 12,500 shares on Jun 30, 2026.
- Latest filings: 8-K Aug 21, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 32.58M shares outstanding (Jul 31, 2026), +28.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NVCT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 18.89 | 18.89 | 17.81 | 18.60 | 158.42K |
| Oct 15, 2026 | 18.30 | 19.59 | 18.30 | 18.93 | 156.90K |
| Oct 14, 2026 | 18.27 | 18.72 | 17.68 | 18.00 | 184.20K |
| Oct 13, 2026 | 19.59 | 19.88 | 18.01 | 18.15 | 215.80K |
| Oct 12, 2026 | 21.12 | 21.19 | 19.55 | 19.69 | 145.80K |
| Oct 9, 2026 | 20.11 | 21.29 | 19.88 | 21.12 | 153.00K |
| Oct 8, 2026 | 20.05 | 20.42 | 19.60 | 20.13 | 179.40K |
| Oct 7, 2026 | 19.67 | 20.72 | 19.67 | 20.29 | 121.10K |
| Oct 6, 2026 | 21.54 | 21.54 | 19.79 | 20.03 | 188.10K |
| Oct 5, 2026 | 22.00 | 22.24 | 20.29 | 21.39 | 194.30K |
| Oct 2, 2026 | 21.11 | 22.00 | 21.04 | 21.92 | 207.50K |
| Oct 1, 2026 | 21.33 | 21.90 | 20.53 | 20.72 | 168.30K |
| Sep 30, 2026 | 20.73 | 21.62 | 20.41 | 21.12 | 240.30K |
| Sep 29, 2026 | 20.91 | 21.40 | 20.11 | 20.53 | 160.00K |
| Sep 28, 2026 | 20.00 | 21.24 | 19.55 | 20.81 | 137.90K |
| Sep 25, 2026 | 21.81 | 21.95 | 20.22 | 20.22 | 191.80K |
| Sep 24, 2026 | 21.38 | 21.99 | 20.65 | 21.63 | 258.20K |
| Sep 23, 2026 | 23.00 | 23.00 | 20.94 | 21.07 | 169.20K |
| Sep 22, 2026 | 22.26 | 23.17 | 21.78 | 23.00 | 124.00K |
| Sep 21, 2026 | 22.02 | 22.39 | 21.40 | 21.98 | 166.40K |
About Nuvectis Pharma
Nuvectis Pharma (NVCT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FORT LEE, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1875558.
NVCT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ron Bentsur | Chairman & CEO | Jul 1, 2026 |
| Kenneth Hoberman | Director | Jun 12, 2026 |
| Matthew L. Kaplan | Director | Jun 12, 2026 |
| James F Iii Oliviero | Director | Jun 12, 2026 |
| Juan Sanchez | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ron Bentsur | Chairman & CEO | Jul 1, 2026 |
| Michael J. Carson | Vice President, Finance | Aug 5, 2026 |
| Enrique Poradosu | Chief Science & Business Off | Jan 9, 2026 |
| Shay Shemesh | Chief Dev. & Ops. Officer | Jan 9, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 30, 2026 | Ron Bentsur | Buy | 12,500 | $20.00 |
| Jun 30, 2026 | Ron Bentsur | Buy | 12,500 | $20.00 |
| Jun 30, 2026 | Ron Bentsur | Buy | 12,500 | $20.00 |
| Jun 30, 2026 | Ron Bentsur | Buy | 12,500 | $20.00 |
| Jun 30, 2026 | Marlio Charles Mosseri | Buy | 50,000 | $18.32 |
| Jun 30, 2026 | Marlio Charles Mosseri | Buy | 50,000 | $18.32 |
| Jun 30, 2026 | Marlio Charles Mosseri | Buy | 50,000 | $18.32 |
| Jun 30, 2026 | Marlio Charles Mosseri | Buy | 50,000 | $18.32 |
| Nov 5, 2025 | Matthew L. Kaplan | Buy | 11,000 | $5.84 |
| Nov 5, 2025 | Matthew L. Kaplan | Buy | 11,000 | $5.84 |
| Nov 5, 2025 | Matthew L. Kaplan | Buy | 11,000 | $5.84 |
| Nov 5, 2025 | Matthew L. Kaplan | Buy | 11,000 | $5.84 |
| Nov 5, 2025 | Juan Sanchez | Buy | 13,000 | $5.79 |
| Nov 5, 2025 | Juan Sanchez | Buy | 13,000 | $5.79 |
| Nov 5, 2025 | Juan Sanchez | Buy | 13,000 | $5.79 |
NVCT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-26.44M | -1.32 | $-16.01M |
| Dec 31, 2024 | — | $-19.00M | -1.11 | $-12.25M |
| Dec 31, 2023 | — | $-22.26M | -1.43 | $-15.95M |
| Dec 31, 2022 | — | $-19.09M | -1.51 | $-13.56M |
| Dec 31, 2021 | — | $-12.89M | -3.02 | $-9.50M |
Latest balance sheet: total assets $22.38M, total liabilities $13.29M, cash $22.16M (as of Jun 30, 2026).
NVCT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $20.10 |
| May 5, 2026 | 8-K Item 2.02 (results) | $9.71 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $8.78 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $5.88 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $6.90 |
| May 6, 2025 | 8-K Item 2.02 (results) | $8.96 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $6.93 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $7.43 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 5, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NVCT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.